| abstract |
The present invention relates to combinations for the treatment or prophylaxis of non-Hodgkin's lymphoma (NHL) from a) a compound of 2,3-dihydroimidazo [1,2-c] quinazoline, namely 2-amino-N- [7-methoxy-8- (3- morpholin-4-ylpropoxy) -2,3-dihydroimidazo [1,2-c] quinazolin-5-yl] pyrimidin-5-carboxamide and b) one or more additional active agents selected from the group consisting of a PI3Kδ-selective inhibitor GS-1101, BTK inhibitor ibrutinib, IKK inhibitor BAY compound B and refametinib (BAY 86-9766 (RDEA-119)), wherein non-Hodgkin’s lymphoma (NHL) is selected from first-line, second-line, recurrent, refractory lymphoma, indolent or aggressive non-Hodgkin’s lymphoma (NHL), in particular follicular lymphoma (PL), chronic lymphocytic leukemia (CLL), marginal zone lymphoma (LMZ), diffuse large-cell lymphoma (DVLC), mantle cell lymphoma (MKL), transformed lymphoma ( ) or peripheral T-cell lymphoma (PTCL); a pharmaceutical composition for treating or preventing non-Hodgkin lymphoma (NHL) comprising a combination of a) said compound and b) said one or more additional active agents. |